Last reviewed · How we verify
Tacrolimus, Myfortic and Sirolimus — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Tacrolimus, Myfortic and Sirolimus (Tacrolimus, Myfortic and Sirolimus) — University of Miami.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tacrolimus, Myfortic and Sirolimus TARGET | Tacrolimus, Myfortic and Sirolimus | University of Miami | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tacrolimus, Myfortic and Sirolimus CI watch — RSS
- Tacrolimus, Myfortic and Sirolimus CI watch — Atom
- Tacrolimus, Myfortic and Sirolimus CI watch — JSON
- Tacrolimus, Myfortic and Sirolimus alone — RSS
Cite this brief
Drug Landscape (2026). Tacrolimus, Myfortic and Sirolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/tacrolimus-myfortic-and-sirolimus. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab